Aridis pharmaceuticals, inc. (ARDS)
CashFlow / Yearly
Dec'19Dec'18Dec'17
Cash flows from operating activities:
Net loss

-29,681

-22,105

-24,656

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

338

283

62

Stock-based compensation expense

2,010

1,658

1,608

Share of loss from equity method investment

-951

-40

-

Change in fair value of preferred stock warrants

-

-1,632

5,152

Changes in operating assets and liabilities:
Accounts receivable

-1,660

1,660

-67

Other receivables

-25

-

-

Prepaid expenses

1,433

2,207

37

Contract costs

1,576

-

-

Other assets

-438

648

304

Accounts payable

-469

1,297

-

Accrued liabilities

-2

800

-

Deferred revenue

19,580

-97

120

Accounts payable, accrued liabilities and other

-

-

431

Net cash used in operating activities

-8,159

-24,271

-17,557

Cash flows from investing activities:
Purchase of equity method investment

174

677

-

Purchase of property and equipment

-

1,000

698

Net cash used in investing activities

-174

-1,677

-698

Cash flows from financing activities:
Proceeds from issuance of preferred stock, net

-

-

21,060

Proceeds from issuance of common stock, net

4,958

25,079

-

Proceeds from stock option exercises

35

10

-

Net cash provided by financing activities

4,993

25,089

21,060

Net decrease in cash and cash equivalents

-3,340

-859

2,805

Supplemental cash flow disclosures:
Cash paid for taxes

2

2

1

Supplemental noncash investing and financing activities:
Preferred stock dividends accrued

-

1,357

-

Preferred stock dividends issued

-

-

2,793

Reclassification of warrant liability into equity

-

10,236

-

Issuance of common stock warrants attributed to private offerings

-

-

352

Property and equipment additions

13

120

-